The World's Largest PDX and
primary 3d cell culture capability
140,000 viable, clinically annotated, primary human
tumors for pharmacology and biomarker studies
When: October 23rd, 10 am PST
Live with real time Q&A
Attend if you are interested in:
- Transactional medicine
- Biomarker discovery and validation
- Pre-clinical models
- Drug candidate prioritization
- Patient stratification
Tommy Broudy, Ph.D.
CSO, Molecular Response
Dr. Broudy will discuss the use of patient-derived tumor banks to create more clinically-relevant in vivo and ex vivo models in support of oncology drug development. While cell line studies have been the main stay of oncology research for more than half a century, the ability to directly test drug efficacy on populations of patient tumors offers a translational approach toward forming more confident clinical development in the preclinical setting.
Recent advances in technology and method have enabled unprecedented science; ex vivo systems now combine 3D primary tumor cell culture with high content imaging, while in vivo systems rely on mouse hospitals featuring patient derived xenograft models in preclinical trial studies.
This webinar will focus on some of the advances our field have made to study the efficacy of anticancer agents before their actual trial in man–to identify successful indications, predictive markers of response, and effective combination therapies.